Roth Capital Partners analyst Jotin Marango resumed coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $10 price target. The stock closed at $1.82 on Jan. 25. “We like the breadth and optionality of...
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay (NYSE American:ISR) with a “buy” rating and price target of 70 cents, saying the company is “at an inflection point of sustainable revenue growth...
Roth Capital Partners launched coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and price target of $10.50. The stock closed at $2.25 on Jan. 25. AzurRx is developing non-systemic, recombinant enzyme...
Maxim Group initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $3 price target. The stock closed at 67 cents on Jan. 23. Bellerophon’s lead product is the INOpulse delivery system of...
In a new report, Alliance Global Partners analyst Ben Haynor writes that investors appear to have ignored the potential of Profound Medical’s (OTCQX:PRFMF; TSX:PRN) TULSA-PRO MRI-guided ablation system for the treatment...
Paradigm Capital launched coverage of CannTrust Holdings (TSX:TRST) with a “buy” rating and $18 price target. The stock closed at $8.35 on Jan.18. “CannTrust brings to the cannabis space a practice of professionalism...
H.C. Wainwright raised its price target for Aeterna Zentaris (NASDAQ, TSX:AEZS) to $5.50 from $3 after its Macrilen agent for adult growth hormone deficiency (AGHD) was approved for sale in the EU. The stock closed at...
Leerink launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “market perform” rating and $21 price target. The stock closed at $25.33 on Jan. 16. Puma is a single-product commercial-stage biotech company...
Echelon Wealth Partners initiated coverage of Kalytera Therapeutics (TSXV:KALY) with a “speculative buy” rating and price target of 30 cents. The stock closed at 8.5 cents on Jan. 14. Kalytera is developing the...
Noble Capital Markets initiated coverage of Dyadic International (OTC:DYAI) with an “outperform” rating and price target of $4. The stock closed at $1.96 on Jan. 9. Over the past two decades, Dyadic has developed an...